DARA Biosciences Inc., an American pharmaceutical company, has announced that the FDA has granted Orphan Drug Designation for its investigational drug KRN5500 for the treatment of myeloma. KRN5500 is a novel, intravenous, non-opioid, non-narcotic compound currently being developed for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy. Pre-clinical studies show that KRN5500, a spicimycin derivative, also exhibits anti-myeloma effects through inhibition of both myeloma cells and osteoclasts. The new orphan drug designation will enable the company to further develop KRN5500 as a potential treatment for myeloma.

Read the full article ยป